Suven Life Sciences secures product patent in USA

Suven Life Sciences’ drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators which resulted in the grant of one product patent from USA, corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and this patent is valid through 2030. The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by the company and are being developed as therapeutic agents for major depressive disorder (MDD). With this new patent, the company has a total of eighteen granted patents from USA. These granted patents are exclusive intellectual property of the company and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II. Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.